CME credits: 0.75

Valid until: 28-07-2023

Claim your CME credit at https://reachmd.com/programs/cme/conversations-about-pah-latest-developments-and-key-insights-for-2023-foundational-activity/14913/

Pulmonary arterial hypertension (PAH) is a chronic and progressive disease that affects the pulmonary vasculature, leading to increased pulmonary vascular resistance, right ventricular dysfunction, and ultimately, right heart failure. Early identification and management of PAH is crucial to improve patient outcomes. This requires a thorough understanding of the diagnostic criteria and classification of PAH, as well as an evidence-based approach to care that incorporates guideline recommendations, latest developments, and key insights from leading professional organizations. Moreover, given the limitations of current therapies, there is a need to critically review novel treatment pathways and new/emerging therapeutic targets for PAH.

In this clinical discussion, you'll hear from two leading experts who will share recent evidence and highlights from the 2023 American College of Cardiology Annual Meeting that supports using novel agents for PAH. As part of the discussion, they also discuss how you can optimize PAH treatment plans and integrate the latest guideline recommendations in your practice.

=